Literature DB >> 25238203

miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1.

Marianna Colamaio1, Francesca Puca, Elvira Ragozzino, Marica Gemei, Myriam Decaussin-Petrucci, Concetta Aiello, André Uchimura Bastos, Antonella Federico, Gennaro Chiappetta, Luigi Del Vecchio, Liborio Torregrossa, Sabrina Battista, Alfredo Fusco.   

Abstract

CONTEXT: A previous micro-RNA expression profile of thyroid follicular adenomas identified miR-142 precursor among the miRNAs downregulated in the neoplastic tissues compared to normal thyroid gland.
OBJECTIVE: The aim of this work has been to assess the expression of miR-142-3p in a large panel of follicular thyroid adenomas and carcinomas and evaluate its effect on thyroid cell proliferation and target expression.
DESIGN: The expression of miR-142-3p was analyzed by qRT-PCR in thyroid follicular adenomas and carcinomas, compared to normal thyroids. MiR-142-3p expression was restored in WRO cells and the effects on cell proliferation and target expression were evaluated.
RESULTS: Here we show that miR-142-3p is downregulated in FTAs, FTCs, and FVPTCs. MiR-142-3p was demonstrated to reduce the proliferation rate of WRO and FTC133 cells, supporting its tumor suppressor role in thyroid cancerogenesis. Moreover, this microRNA was able to downregulate the expression of ASH1L and MLL1, by direct and indirect mechanisms, respectively. Consistently, an inverse correlation between miR-142-3p expression and ASH1L and MLL1 proteins was found in thyroid follicular adenomas and carcinomas. ASH1L and MLL1, which belong to the Trithorax group (TrxG) proteins and are major regulators of Homeobox gene expression, maintain active target gene transcription by histone 3 lysine 4 methylation. Interestingly, we found that FTCs and FTC cell lines express tumor specific, shorter forms of the two proteins. The capability of miR-142-3p to modulate the levels of these tumor-associated forms and to reactivate thyroid-specific Hox gene expression, likely contributes to its tumor suppressive function.
CONCLUSIONS: These data demonstrate that miR-142-3p downregulation has a role in thyroid tumorigenesis, by regulating ASH1L and MLL1.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25238203     DOI: 10.1210/jc.2014-2280

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  Downregulation of microRNA-142-3p and its tumor suppressor role in gastric cancer.

Authors:  Yi Wang; Zhidong Cao; Lanlan Wang; Siqi Liu; Jianqiang Cai
Journal:  Oncol Lett       Date:  2018-03-23       Impact factor: 2.967

2.  Two Loops Undergoing Concerted Dynamics Regulate the Activity of the ASH1L Histone Methyltransferase.

Authors:  David S Rogawski; Juliano Ndoj; Hyo Je Cho; Ivan Maillard; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Biochemistry       Date:  2015-08-25       Impact factor: 3.162

Review 3.  H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.

Authors:  David S Rogawski; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2016-08-22       Impact factor: 3.808

Review 4.  Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes.

Authors:  Maryam Zarkesh; Azita Zadeh-Vakili; Fereidoun Azizi; Forough Foroughi; Maziar Mohammad Akhavan; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

5.  Oncogenic microRNA-142-3p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma.

Authors:  Yifan Li; Duqun Chen; L U Jin; Jiaju Liu; Yuchi Li; Zhengming Su; Zhengyu Qi; Min Shi; Zhimao Jiang; Shangqi Yang; Yaoting Gui; Xiangming Mao; Xionghui Wu; Yongqing Lai
Journal:  Oncol Lett       Date:  2015-12-10       Impact factor: 2.967

Review 6.  Structural and functional specificity of H3K36 methylation.

Authors:  Ulysses Tsz Fung Lam; Bryan Kok Yan Tan; John Jia Xin Poh; Ee Sin Chen
Journal:  Epigenetics Chromatin       Date:  2022-05-18       Impact factor: 5.465

7.  Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.

Authors:  Bin Xu; Tingting Qin; Jingcheng Yu; Thomas J Giordano; Maureen A Sartor; Ronald J Koenig
Journal:  J Biol Chem       Date:  2020-05-12       Impact factor: 5.157

8.  MicroRNAs and their target mRNAs as potential biomarkers among smokers and non-smokers with lung adenocarcinoma.

Authors:  Sumaria Malik; Rehan Zafar Paracha; Maryam Khalid; Maryum Nisar; Amnah Siddiqa; Zamir Hussain; Raheel Nawaz; Amjad Ali; Jamil Ahmad
Journal:  IET Syst Biol       Date:  2019-04       Impact factor: 1.615

9.  Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity.

Authors:  David S Rogawski; Jing Deng; Hao Li; Hongzhi Miao; Dmitry Borkin; Trupta Purohit; Jiho Song; Jennifer Chase; Shuangjiang Li; Juliano Ndoj; Szymon Klossowski; EunGi Kim; Fengbiao Mao; Bo Zhou; James Ropa; Marta Z Krotoska; Zhuang Jin; Patricia Ernst; Xiaomin Feng; Gang Huang; Kenichi Nishioka; Samantha Kelly; Miao He; Bo Wen; Duxin Sun; Andrew Muntean; Yali Dou; Ivan Maillard; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Nat Commun       Date:  2021-05-14       Impact factor: 14.919

10.  MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis.

Authors:  Maria C Trissal; Terrence N Wong; Juo-Chin Yao; Rahul Ramaswamy; Iris Kuo; Jack Baty; Yaping Sun; Gloria Jih; Nishi Parikh; Melissa M Berrien-Elliott; Todd A Fehniger; Timothy J Ley; Ivan Maillard; Pavan R Reddy; Daniel C Link
Journal:  Cancer Res       Date:  2018-05-03       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.